41191-04-2|Triazinate|3-[[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenoxy]methyl]-N,N-dimethylbenzamide;ethanesulfonic acid|-范德生物科技公司

Triazinate

NMR下载 COA and HPLC MSDS下载
names：
3-[[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenoxy]methyl]-N,N-dimethylbenzamide;ethanesulfonic acid
CAS号：
41191-04-2
MDL Number：
MF(分子式)： C23H30ClN6O5S MW(分子量)： 538.04
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK20345-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	3-[[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenoxy]methyl]-N,N-dimethylbenzamide;ethanesulfonic acid
英文别名	Triazinate; TZT
CAS号	41191-04-2
Inchi	InChI=1S/C23H30ClN6O5S/c1-23(2)28-21(25)27-22(26)29(23)17-8-9-19(18(24)13-17)35-14-15-6-5-7-16(12-15)20(31)30(3,4)10-11-36(32,33)34/h5-9,12-13H,10-11,14H2,1-4H3,(H,32,33,34)(H4,25,26,27,28)
InchiKey	IROWRJNCUILBPD-UHFFFAOYSA-N
分子式 Formula	C23H30ClN6O5S
分子量 Molecular Weight	538.04
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Triazinate(CAS:41191-04-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Triazinate is an anti-tumor compound.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kalghatgi KK, Moroson BA, Horváth C, Bertino JR. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G[1]Cancer Res. 1979 Sep;39(9):3441-5. PubMed PMID: 476673.

[2]Gralla EJ, Coleman GL, Osbaldiston W, Sawicki WL, Jonas RM, Bertino JR. Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys. Cancer Chemother Rep. 1975 May-Jun;59(3):523-30. PubMed PMID: 812604.

[3] Greenspan AH, Shupack JL, Foo SH, Wise AC. Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy. Arch Dermatol. 1985 Feb;121(2):232-5. PubMed PMID: 3977338.

[4] Skeel RT, Cashmore AR, Sawicki WL, Bertino JR. Clinical and pharmacological evaluation of triazinate in humans. Cancer Res. 1976 Jan;36(1):48-54. PubMed PMID: 1248009.

[5] Skeel RT, Sawicki WL, Cashmore AR, Bertino JR. Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate. Cancer Res. 1976 Oct;36(10):3659-64. PubMed PMID: 953990.

6: O'Connell MJ, Schutt AJ, Moertel CG, Rubin J, Hahn RG, Scott M. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 1987 Aug;10(4):320-4. PubMed PMID: 3303905.7: Chello PL, McQueen CA, DeAngelis LM, Bertino JR. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists. Cancer Res. 1976 Jul;36(7 PT 1):2442-9. PubMed PMID: 1277151.8: Camerman A, Smith HW, Camerman N. Stereochemistry of dihydrofolate reductase inhibitor antitumor agents: molecular structure of "Baker's antifol" (NSC 139105, triazinate) and "insoluble Baker's antifol" (NSC 113423). Biochem Biophys Res Commun. 1978 Jul 14;83(1):87-93. PubMed PMID: 697826.9: Townsend JG, Jain RK, Cashmore AR. In vivo pharmacokinetics of triazinate in L-1210 and W-256 cells. J Pharm Sci. 1982 Oct;71(10):1102-5. PubMed PMID: 7143204.10: O'Connell MJ, Schutt AJ, Moertel CG, Hahn RG. Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer. J Clin Oncol. 1987 Jan;5(1):83-5. PubMed PMID: 3100727.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开